La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
STUTTGART, Germany I August 14, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of drug modality technologies available for a R&D organization. La Merie Publishing has released a new service offering which evaluates customer-selected targets...
STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Her3 immunotherapeutics in R&D: Pipeline of Her3-Targeted Immunotherapies. This competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research...
DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis. DLL3 is a clinically validated target for treatment of small cell lung cancer which recently started commercialization. Delta-like...
TSLP (thymic stromal lymphoprotein) is a clinically and commercially validated inflammatory target attracting numerous competitors STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TSLP Inhibitors and TSLP Receptor Antagonists: a Competitor Analysis TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as...
TL1A (TNF-like ligand 1A): the next big, clinically validated target for inflammatory bowel disease STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis TL1A as a target for mainly inflammatory bowel disease recently has received great...
Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis Folate receptor alpha (FRα) is a cell surface...
Fibroblast Activation Protein: an emerging high-value theranostic target for delivery of payloads STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis. Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers,...
Glypican-3 (GPC3): an emerging liver cancer target with opportunities for different effector mechanisms STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis. GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma...
B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis. B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in...
STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an emerging drug modality with potential to overcome several of the limitations of passive immunotherapy with antibodies produced ex vivo. La Merie Publishing released a new report about gene therapy technologies...
